ASTS vs GSK
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 21, 2026
ASTS
GSK
Investment Advisor Scores
GSK
AI Analyst Insights
Detailed Metrics Comparison
| Metric | ASTS | GSK | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 20.5339 | Tie |
| PEG Ratio | 0 | 102.7218 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 2626.6% | 5.3% | ASTS |
| Earnings Growth | 0.0% | -69.5% | ASTS |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 39.6/100 | 54.2/100 | GSK |
| Profit Margin | 0.0% | 14.5% | GSK |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | SELL | STRONG BUY | GSK |
Relative Price Performance (Last 90 Days)
Current Technical Phase
ASTS
NeutralMixed signals - no dominant trend phase, RSI 51
GSK
MarkupPrice above SMA50, rising 50-day trend (0.7% over 20 days), RSI 54
Fundamentals Snapshot
| Metric | ASTS | GSK |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -65.4 | 10.2 |
| Trailing P/E | — | 16.3 |
| Revenue (TTM) | — | — |
| Revenue Growth | 26.3% | 0.1% |
| Gross Margin | 0.4% | 0.7% |
| Operating Margin | -5.4% | 0.3% |
| EPS | -2.11 | 3.19 |
| Dividend Yield | — | 0.04% |